Pancreatic Cancer Research

ResearcherGuiyang Medical UniversityActive in the last 2 years

Hao Hua

ORCID-verified (high confidence, 0.95), identity_conf@1As of 7 November 2026

Matched on ORCID iD 0000-0003-4560-9656; OpenAlex author ID A5024735033. Sources: OpenAlex.

Their work

Papers
9 (first author 2, last author 1)
Trials
0
Grants
0
Labs led
0
Collaborators
20
Papers, trials and grants by year

2019: 1 paper · 2020: 1 paper · 2021: 1 paper · 2022: 1 paper · 2023: 2 papers · 2024: none · 2025: 3 papers

Papers 9

  1. Identification of exosome-related genes associated with prognosis and immune infiltration features in pancreatic cancer. Last author DOI 10.1007/s12672-025-01961-1↗
  2. Causal association between rheumatoid arthritis and pancreatic cancer: a bidirectional two-sample Mendelian randomization study. First author DOI 10.1007/s12672-025-03919-9↗
  3. Senescence-related circRNA circHIF-1α is associated with pancreatic cancer progression. Co-author DOI 10.1186/s12935-025-03645-w↗
  4. FOXQ1 promotes pancreatic cancer cell proliferation, tumor stemness, invasion and metastasis through regulation of LDHA-mediated aerobic glycolysis. Co-author DOI 10.1038/s41419-023-06207-y↗
  5. RNF7 Facilitated the Tumorigenesis of Pancreatic Cancer by Activating PI3K/Akt Signaling Pathway. Co-author DOI 10.1155/2023/1728463↗
  6. The Senescence-Related Signature Predicts Prognosis and Characterization of Tumor Microenvironment Infiltration in Pancreatic Cancer. Co-author DOI 10.1155/2022/1916787↗
  7. ZC3HAV1 promotes the proliferation and metastasis via regulating KRAS in pancreatic cancer. First author DOI 10.18632/aging.203296↗
  8. Long noncoding RNA LINC01559 promotes pancreatic cancer progression by acting as a competing endogenous RNA of miR-1343-3p to upregulate RAF1 expression. Co-author DOI 10.18632/aging.103487↗
  9. MiR-345-5p functions as a tumor suppressor in pancreatic cancer by directly targeting CCL8. Co-author DOI 10.1016/j.biopha.2018.12.121↗

Closest collaborators

The 20 strongest of 20 by collab_strength@1: shared papers, trials and grants, recent and small-team work weighing most.

  1. Chao Yu · 3 shared papers, 2022–2023 · strength 0.60
  2. Zhiwei He · 2 shared papers, 2023–2025 · strength 0.47
  3. Changhao Wu · 2 shared papers, 2023–2025 · strength 0.47
  4. Jie Wang · 2 shared papers, 2019–2025 · strength 0.44
  5. Lingyu Fu · 1 shared paper, 2025 · strength 0.42
  6. Jujie Li · 1 shared paper, 2025 · strength 0.42
  7. Qin Yang · 3 shared papers, 2019–2021 · strength 0.38
  8. Dijie Zheng · 1 shared paper, 2025 · strength 0.27
  9. Chao Yuan Yu · 1 shared paper, 2025 · strength 0.27
  10. Fei Xie · 2 shared papers, 2019–2020 · strength 0.23
  11. Tinggang Mou · 2 shared papers, 2019–2020 · strength 0.23
  12. Jian Zheng · 1 shared paper, 2023 · strength 0.22
  13. Shiyu Chen · 1 shared paper, 2023 · strength 0.20
  14. Cheng-Yi Sun · 1 shared paper, 2023 · strength 0.20
  15. Xiushen Li · 1 shared paper, 2022 · strength 0.17
  16. Wei Huang · 1 shared paper, 2021 · strength 0.16
  17. Lü Jin · 1 shared paper, 2021 · strength 0.16
  18. Jie Wang · 1 shared paper, 2020 · strength 0.12
  19. Xiao Chen · 1 shared paper, 2020 · strength 0.12
  20. Liang Lai · 1 shared paper, 2019 · strength 0.11

How to reach this person

A chain of introductions through people who have published, run trials or held grants together (warm_path@1: fewest links first, then the strongest). Built from public records only; no contact details are kept.